Abstract
6659 Background: High-dose therapy (HDT) with or without total body irradiation followed by autologous stem cell transplantation (ASCT) is a therapeutic option for patients with relapsed or refractory to initial treatment for lymphoma. However, there are relatively few reports regarding outcome following recurrence after HDT therapy. In order to investigate outcome of the HDT, the patterns of recurrence and survival were analyzed. Methods: A total of 61 patients were treated with HDT followed by ASCT between Feb. 1991 and Dec. 2001. In this study, we investigated patterns of relapse and the factor especially bone marrow involvement at time of diagnosis. Results: Fifty-four patients were aggressive lymphoma, 4 were high-grade lymphoma, and 3 were low-grade lymphoma. Involved-field radiotherapy was added to sites of disease, if the sites were indicated after HDT. Median length of follow-up was 70 (24–156) months. Fifty-nine patients were assessable. Forty nine of 59 (83%) patients had complete response or continued CR, and 25 of 49 (51%) patients relapsed at median time of 20.5 (1.4–124.9) months after ASCT. Twelve of 25 patients (48%) relapsed 2 years after HDT. Seventeen of 25 patients (68%) presented with recurrence at previous sites of disease, five patients (20%) at new sites, and three patients (12%) at both previous and new sites. The length of 50% survival of the relapsed patients was 20.7 months. The Kaplan-Meier estimate of patients alive 5 years after recurrence was 13%. We analyzed relapse pattern according to bone marrow involvement. The results were shown in the table. The relapse patterns and survival after HDT followed by ASCT were identical in both groups. Conclusions: The HDT followed by ASCT might be able to save some group of refractory lymphoma patients regardless of bone marrow involvement. No significant financial relationships to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
